Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat obesity.

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.